Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape
Snapshot: 2026-10-21

Shaanxi Multiple Myeloma Active Trials & Centers

As of 2026-10-21, there are 24 active clinical trials for multiple myeloma hosted across 15 tertiary medical centers in Shaanxi (including The Second Affiliated Hospital of Xi'an Jiaotong University, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Central Hospital, etc.).

Active Trials
24
Hospitals
15
Therapies
CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (15)

The Second Affiliated Hospital of Xi'an Jiaotong UniversityThe First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an Central HospitalBaoji Central HospitalXianyang Central HospitalXijing Hospital, Air Force Medical UniversityXi'an International Medical Center Co., Ltd.The Second Affiliated Hospital of Xi'an Jiaotong University School of MedicineThe Second Affiliated Hospital of Xi'an Jiaotong UniversityFirst Affiliated Hospital of Air Force Medical University (Xijing Hospital)The Second Affiliated Hospital of Air Force Medical University of the Chinese People's Liberation ArmyThe First Affiliated Hospital of PLA Air Force Medical UniversityThe Second Affiliated Hospital of Xi'an Jiaotong UniversityShaanxi Provincial People's HospitalThe First Affiliated Hospital of Air Force Medical University (Xijing Hospital)

Active Studies in Shaanxi (24)

Population synthesized by CMDN

Showing 0 published English records of 24 registry trials.

All 24 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.